Categorized | Scientific Publications

Melanoma Journal Articles for April 2018

Clinical Cancer Research
The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma
Jessica Yang, Omid Hamid and Richard D. Carvajal
DOI: 10.1158/1078-0432.CCR-18-0020

Journal of Translational Medicine

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Michael F. Gowen, Keith M. Giles, Danny Simpson, Jeremy Tchack, Hua Zhou, Una Moran, Zarmeena Dawood, Anna C. Pavlick, Shaohui Hu, Melissa A. Wilson, Hua Zhong, Michelle Krogsgaard, Tomas Kirchhoff and Iman Osman
Journal of Translational Medicine201816:82
Received: 10 January 2018
Accepted: 15 March 2018
Published: 2 April 2018

Dove Press

miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells

Authors Chen G, Xie Y
Received 22 September 2017
Accepted for publication 31 December 2017
Published 5 April 2018 Volume 2018:11 Pages 1909—1920

Management of Metastatic Melanoma in 2018

Howard L. Kaufman, MD1Kim Margolin, MD2Ryan Sullivan, MD3
JAMA Oncol. Published online April 5, 2018. doi:10.1001/jamaoncol.2018.0170

Cancer Discovery

Immune Checkpoint Blockade Is Active in Melanoma Brain Metastases

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. 
DOI: 10.1158/2159-8290.CD-RW2018-058
Published OnlineFirst April 6, 2018

Annals of Surgical Oncology
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma
Moran Amit, MD, PhD1 , Samantha Tam, MD1 , Ahmed S. Abdelmeguid, MD1 , Michael E. Kupferman, MD1 , Shirley Y. Su, MBBS1 , Shaan M. Raza, MD2 , Franco DeMonte, MD2 , and Ehab Y. Hanna, MD1,3
First Online: 06 April 2018

Case Reports in Plastic Surgery and Hand Surgery 

Development of a primary melanoma in situ within a full-thickness skin graft overlying a free muscle flap: a case report

Robert J. DabekNemanja Baletic,Harrison McUmber,Brian Nahed,Alex Haynes,Kyle R. Eberlin & show all
Pages 23-26 | Received 22 Jan 2018, Accepted 10 Mar 2018, Published online: 06 Apr 2018

Annals of Oncology

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

J Lewin L Sayers D Kee I Walpole A Sanelli L te Marvelde A Herschtal J SpillaneD Gyorki D Speakman  Show more
Author Notes
Annals of Oncology, mdy124,
Published:  12 April 2018

Science – Translational medicine

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

Natalie J. Neubert1,*Martina Schmittnaegel2,*Natacha Bordry1,*Sina Nassiri2Noémie Wald1Christophe Martignier1Laure Tillé1Krisztian Homicsko1,2William Damsky3Hélène Maby-El Hajjami1Irina Klaman4Esther Danenberg5Kalliopi Ioannidou1Lana Kandalaft5George Coukos1,5Sabine Hoves4Carola H. Ries4
Silvia A. Fuertes Marraco1Periklis G. Foukas5,Michele De Palma2,,§ and 
Daniel E. Speiser1,,§
Science Translational Medicine 11 Apr 2018:
Vol. 10, Issue 436, eaan3311
DOI: 10.1126/scitranslmed.aan3311

Journal of the national cancer institute

A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma

Craig C Teerlink Chad Huff Jeff Stevens Yao Yu Sheri L Holmen Mark R SilvisKirby Trombetti Hua Zhao Douglas Grossman James M Farnham  Show more
Author Notes
JNCI: Journal of the National Cancer Institute, djy058,
Published: 11 April 2018

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

The Lancet. Oncology, ISSN: 1474-5488
Publication Year: 2018

BMC Cancer

MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells

Yuxia Li, Jie Zhang, Yajing Liu, Bingyue Zhang, Fubo Zhong, Shubin Wang and Zhengyu Fang
BMC Cancer201818:404
Received: 20 September 2017
Accepted: 15 March 2018
Published: 11 April 2018

Clinical Cancer Research

BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody

Martina Sanlorenzo, Igor Vujic, Arianna Floris, Mauro Novelli, Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Ramona Rotolo, Chiara Donini, Marco Basiricò, Pietro Quaglino, Maria Teresa Fierro, Silvia Giordano, Maria Sibilia, Fabrizio Carnevale-Schianca, Massimo Aglietta and Dario Sangiolo
DOI: 10.1158/1078-0432.CCR-17-1914

Cancer Discovery

Adjuvant Therapy for Melanoma Prolongs RFS

DOI: 10.1158/2159-8290.CD-NB2018-047
Published OnlineFirst April 15, 2018

New England Journal of Medicine

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, M.D., Ph.D., Christian U. Blank, M.D., Ph.D., Mario Mandala, M.D., Georgina V. Long, M.D., P.D., Victoria Atkinson, M.D., Stéphane Dalle, M.D., Andrew Haydon, M.D., Mikhail Lichinitser, M.D., Adnan Khattak, M.D., Matteo S. Carlino, M.D., Ph.D., Shahneen Sandhu, M.D., James Larkin, M.D., et al.
April 15, 2018
DOI: 10.1056/NEJMoa1802357

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017

Paolo A. Ascierto, Corrado Caracò, Jeffrey E. Gershenwald, Omid Hamid, Merrick Ross, Ryan J. Sullivan and Igor Puzanov
Journal of Translational Medicine201816:101
Received: 20 March 2018
Accepted: 6 April 2018
Published: 17 April 2018

Journal of Surgical Oncology

Intralesional PV?10 for the treatment of in?transit melanoma metastases—Results of a prospective, non?randomized, single center study

Tavis A. Read BMedSc, MBBS, Aaron Smith BMedSc, MBBS, Janine Thomas BHSc, Michael David BSc Hons, MSc, PhD, Matthew Foote MBBS, FRANZCR, Michael Wagels BMedSc, MBBS, PhD, FRACS, Andrew Barbour MBBS, PhD, FRACS, B. Mark Smithers MBBS, FRACS, FRCS Eng
First published: 12 March 2018

JAMA Ophthalmology – Ophthalmic Images
March 8, 2018

Cutaneous Melanoma Metastatic to Anterior Lens Capsule

Samantha K. Paul, ScB1Lin Chou, MD2Carol L. Shields, MD3
JAMA Ophthalmol. 2018;136(3):e180095. doi:10.1001/jamaophthalmol.2018.0095

The Lancet

Novel gene variant for melanoma predisposition

Manjulika Das
Published: 19 April 2018

Clinical Cancer Research

Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

Zeynep Eroglu, Yian Ann Chen, Geoffrey T Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I Khushalani, Joseph Markowitz, Andrew S Brohl, Leticia F. Tetteh, Howida Ramadan, Gina Arnone, Jiannong Li, Xiuhua Zhao, Ritin Sharma, Lancia N.F. Darville, Bin Fang, Inna Smalley, Jane L. Messina, John M. Koomen, Vernon K. Sondak and Keiran S.M. Smalley
DOI: 10.1158/1078-0432.CCR-18-0565


The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent.

 View ORCID ProfileChloe May Simpson, Chris Bakal
Posted April 23, 2018.

Biomolecules 20188(2), 21;

Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine

Sophie L. Mumford 1,Benjamin P. Towler 1,Amy L. Pashler 1,Onur Gilleard 2,Yella Martin 3 and Sarah F. Newbury 1,
Received: 9 March 2018 / Revised: 20 April 2018 / Accepted: 23 April 2018 / Published: 26 April 2018

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

Hao Liu , Amy Weber , Jennifer Morse, Krithika Kodumudi, Ellen Scott, John Mullinax, Amod A. Sarnaik , Shari Pilon-Thomas